These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 18028026)

  • 1. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
    O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance mechanisms in cancer cells: a proteomics perspective.
    Verrills NM; Kavallaris M
    Curr Opin Mol Ther; 2003 Jun; 5(3):258-65. PubMed ID: 12870435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in clinical oncoproteomics.
    Jain KK
    J BUON; 2007 Sep; 12 Suppl 1():S31-8. PubMed ID: 17935275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms of drug resistance.
    Longley DB; Johnston PG
    J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncoproteomics.
    Joshi S; Tiwari AK; Mondal B; Sharma A
    Clin Chim Acta; 2011 Jan; 412(3-4):217-26. PubMed ID: 20955692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer.
    Li XH; Li C; Xiao ZQ
    J Proteomics; 2011 Nov; 74(12):2642-9. PubMed ID: 21964283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer proteomics and its application to discovery of therapy response markers in human cancer.
    Smith L; Lind MJ; Welham KJ; Cawkwell L;
    Cancer; 2006 Jul; 107(2):232-41. PubMed ID: 16752413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer.
    Chapal N; Molina L; Molina F; Laplanche M; Pau B; Petit P
    Fundam Clin Pharmacol; 2004 Aug; 18(4):413-22. PubMed ID: 15312147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance mechanisms in human lung cancer.
    Mattern J; Volm M
    Invasion Metastasis; 1995; 15(3-4):81-94. PubMed ID: 8621273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncoproteomics: current trends and future perspectives.
    Cho WC; Cheng CH
    Expert Rev Proteomics; 2007 Jun; 4(3):401-10. PubMed ID: 17552924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting cancer drug response by proteomic profiling.
    Ma Y; Ding Z; Qian Y; Shi X; Castranova V; Harner EJ; Guo L
    Clin Cancer Res; 2006 Aug; 12(15):4583-9. PubMed ID: 16899605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular-target drug].
    Sone S; Yano S; Nishioka Y
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1034-40. PubMed ID: 15272581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular perspectives on the non-responder phenomenon.
    Jackson DB
    Drug Discov Today; 2009 Apr; 14(7-8):373-9. PubMed ID: 19200455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stochastic modeling of drug resistance in cancer.
    Komarova N
    J Theor Biol; 2006 Apr; 239(3):351-66. PubMed ID: 16194548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug resistance reversal agents.
    Robert J; Jarry C
    J Med Chem; 2003 Nov; 46(23):4805-17. PubMed ID: 14584929
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death.
    Hazlehurst LA; Landowski TH; Dalton WS
    Oncogene; 2003 Oct; 22(47):7396-402. PubMed ID: 14576847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretation of treatment results with biological agents: is there a need for a new methodology?
    Begent RH
    J BUON; 2007 Sep; 12 Suppl 1():S53-8. PubMed ID: 17935278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.
    El Maalouf G; Le Tourneau C; Batty GN; Faivre S; Raymond E
    Cancer Treat Rev; 2009 Apr; 35(2):167-74. PubMed ID: 19027240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug resistance in cancer therapy: role of the microenvironment.
    Galmarini CM; Galmarini FC
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1416-21. PubMed ID: 14763126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
    Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
    Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.